Esperion Therapeutics | ESPR - Loan Capital


Esperion Therapeutics reported $457.65M in Loan Capital for its fiscal quarter ending in December of 2025.





Loan Capital Change Date
AbbVie USD 58.94B 4.03B Dec/2025
Alnylam Pharmaceuticals USD 2.48B 931K Mar/2026
Alterity Therapeutics Limited AUD 43.68K 59.53K Dec/2025
Amgen USD 51.89B 1.88B Mar/2026
Biogen USD 6.29B 1.7M Mar/2026
BioMarin Pharmaceutical USD 1.43B 833.11M Mar/2026
Cipla INR 3.82B 840.2M Mar/2026
CSL USD 10.42B 273M Dec/2025
Cytokinetics USD 247.21M 868.77M Mar/2026
Daiichi Sankyo JPY 300.15B 199.41B Dec/2025
Eli Lilly USD 39.37B 1.5B Mar/2026
Esperion Therapeutics USD 457.65M 9.5M Dec/2025
Geron USD 119.83M 286K Mar/2026
Grifols EUR 9.95B 722.93M Dec/2025
Halozyme Therapeutics USD 1.94B 206.73M Mar/2026
Heron Therapeutics USD 140.64M 975K Dec/2025
Ionis Pharmaceuticals USD 1.91B 9M Mar/2026
Merck USD 46.67B 77M Mar/2026
Minerva Neurosciences USD 0 86.58M Sep/2024
Moderna USD 603M 7M Mar/2026
Nektar Therapeutics USD 63.16M 44.35M Dec/2025
Pfizer USD 60.57B 1.08B Mar/2026
PTC Therapeutics USD 286.94M 1.74B Mar/2026
Puma Biotechnology USD 10.87M 222K Jun/2025
Regeneron Pharmaceuticals USD 1.99B 719.7M Mar/2026
Sanofi EUR 13.84B 1.88B Mar/2026
Sarepta Therapeutics USD 838.16M 9.19M Mar/2026
United Therapeutics USD 100M 100M Jun/2024
Vanda Pharmaceuticals USD 3.15M 3.15M Dec/2024